Titlebook: Resistance to Immunotherapeutic Antibodies in Cancer; Strategies to Overco Benjamin Bonavida Book 2013 Springer Science+Business Media New

同步左右

Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer, been proven that patients with mutations in exon 2 of the . ongogene gain no benefit from treatment with the monoclonal antibodies (moAbs) against Epidermal Growth Factor Receptor (EGFR), cetuximab and panitumumab. Currently, the determination of . mutational status represents a paradigm for biomar

憤憤不平

切碎

Resection

詞匯

Antibody-Drug Conjugates: Can Coupling Cytotoxicity and Specificity Overcome Therapeutic Resistanceer component provides the ADC with an antibody’s exquisite selectivity for its target antigen, which is typically a cell surface molecule with a tumor-restricted expression pattern. The latter component provides the ADC with a highly potent cytotoxic payload that can efficiently kill targeted cells